Catalog No.
MVV04904
Species reactivity
Human herpesvirus 2 (HSV-2/HHV-2)
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Immunogen
E. coli - derived recombinant HHV-2 gD / US6 (Lys26-Pro339).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:500-1:4000
Target
Envelope glycoprotein D,gD,US6
Concentration
1.6 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P03172
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
1A150
A potent protective bispecific nanobody targeting Herpes simplex virus gD reveals vulnerable epitope for neutralizing., PMID:40328740
[Preparation and efficacy of a circRNA vaccine with herpes simplex virus type Ⅱ gD as immunogen]., PMID:40328701
Targeting Herpes Simplex Virus Glycoprotein D with Bispecific Antibodies: Expanding Therapeutic Horizons by Searching for Synergy., PMID:40007004
Development and application of an uncapped mRNA platform., PMID:39648715
A nonhuman primate model for genital herpes simplex virus 2 infection that results in vaginal vesicular lesions, virus shedding, and seroconversion., PMID:39226323
Human Antibodies against Herpes Simplex Virus 2 Glycoprotein G Do Not Neutralize but Mediate Antibody-Dependent Cellular Cytotoxicity., PMID:38804308
Immunogenicity and Therapeutic Efficacy of a Sendai-Virus-Vectored HSV-2 Vaccine in Mouse and Guinea Pig Models., PMID:38140157
Selection, activity, and nuclease stabilization of cross-neutralizing DNA aptamers targeting HSV-1 and HSV-2., PMID:37925791
Serological status for TORCH in women of childbearing age: a decade-long surveillance (2012-2022) in Italy., PMID:37458733
Comparison of effects of multiple adjuvants and immunization routes on the immunogenicity and protection of HSV-2 gD subunit vaccine., PMID:37290556
A self-binding immune complex vaccine elicits strong neutralizing responses against herpes simplex virus in mice., PMID:37205110
Immunisation Using Novel DNA Vaccine Encoding Virus Membrane Fusion Complex and Chemokine Genes Shows High Protection from HSV-2., PMID:36366414
CCL28 Enhances HSV-2 gB-Specific Th1-Polarized Immune Responses against Lethal Vaginal Challenge in Mice., PMID:36016177
Failure of Herpes Simplex Virus Glycoprotein D Antibodies to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines., PMID:35834278
A potent neutralizing and protective antibody against a conserved continuous epitope on HSV glycoprotein D., PMID:35341808
Preventive Vaccination with Mesenchymal Stem Cells Protects Mice from Lethal Infection Caused by Herpes Simplex Virus 1., PMID:34931092
A recombinant herpes virus expressing influenza hemagglutinin confers protection and induces antibody-dependent cellular cytotoxicity., PMID:34417304
[Preventive Vaccination with Mesenchymal Stem Cells Protects Mice from Lethal Infection Caused by Herpes Simplex Virus 1]., PMID:34097682
CCL19 and CCL28 Assist Herpes Simplex Virus 2 Glycoprotein D To Induce Protective Systemic Immunity against Genital Viral Challenge., PMID:33910988
Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine., PMID:33718970
Contributions of the Four Essential Entry Glycoproteins to HSV-1 Tropism and the Selection of Entry Routes., PMID:33653890
HVEM signaling promotes protective antibody-dependent cellular cytotoxicity (ADCC) vaccine responses to herpes simplex viruses., PMID:32817296
An HSV-2 nucleoside-modified mRNA genital herpes vaccine containing glycoproteins gC, gD, and gE protects mice against HSV-1 genital lesions and latent infection., PMID:32716975
Vaccination Route as a Determinant of Protective Antibody Responses against Herpes Simplex Virus., PMID:32516944
Model of vaccine efficacy against HSV-2 superinfection of HSV-1 seropositive mice demonstrates protection by antibodies mediating cellular cytotoxicity., PMID:32411398
A Single-Cycle Glycoprotein D Deletion Viral Vaccine Candidate, ΔgD-2, Elicits Polyfunctional Antibodies That Protect against Ocular Herpes Simplex Virus., PMID:32295919
Herpes simplex virus type 2 meningitis as a manifestation of Good's syndrome., PMID:31858482
Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects., PMID:30867302
Therapeutic Mucosal Vaccination of Herpes Simplex Virus 2-Infected Guinea Pigs with Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Local Tissue-Resident CD4+ and CD8+ TRM Cells Associated with Protection against Recurrent Genital Herpes., PMID:30787156
Infectivity and growth kinetics of Herpes Simplex Virus type-2 in MOLT4 CCR5+ and CEM CCR5+ T cell lines., PMID:29944889
Prophylactic herpes simplex virus type 2 vaccine adjuvanted with a universal CD4 T cell helper peptide induces long-term protective immunity against lethal challenge in mice., PMID:29857239
The potential of currently unavailable herpes virus vaccines., PMID:29313728
A Herpes Simplex Virus (HSV)-2 Single-Cycle Candidate Vaccine Deleted in Glycoprotein D Protects Male Mice From Lethal Skin Challenge With Clinical Isolates of HSV-1 and HSV-2., PMID:29216362
A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus., PMID:29061442
Interaction between herpesvirus entry mediator and HSV-2 glycoproteins mediates HIV-1 entry of HSV-2-infected epithelial cells., PMID:28809154
Global sensing of the antigenic structure of herpes simplex virus gD using high-throughput array-based SPR imaging., PMID:28614387
Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women., PMID:28493891
The herpevac trial for women: Sequence analysis of glycoproteins from viruses obtained from infected subjects., PMID:28448558
Linear Multiepitope (Glyco)peptides for Type-Specific Serology of Herpes Simplex Virus (HSV) Infections., PMID:28238255
Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir., PMID:28228587
A direct quantitative PCR-based measurement of herpes simplex virus susceptibility to antiviral drugs and neutralizing antibodies., PMID:28093274
An Interleukin 12 Adjuvanted Herpes Simplex Virus 2 DNA Vaccine Is More Protective Than a Glycoprotein D Subunit Vaccine in a High-Dose Murine Challenge Model., PMID:28085634
Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs., PMID:28082979
Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice., PMID:27868164
Intradermal immunisation using the TLR3-ligand Poly (I:C) as adjuvant induces mucosal antibody responses and protects against genital HSV-2 infection., PMID:29263853
B Virus (Macacine Herpesvirus 1) Divergence: Variations in Glycoprotein D from Clinical and Laboratory Isolates Diversify Virus Entry Strategies., PMID:27512063
A recombinant plasmid containing CpG motifs as a novel vaccine adjuvant for immune protection against herpes simplex virus 2., PMID:27357208
Herpes Simplex Virus Type 2 Seroprevalence and Ultrasound-Diagnosed Uterine Fibroids in a Large Population of Young African-American Women., PMID:27188945
Evaluation of a transcription mediated amplification assay for detection of herpes simplex virus types 1 and 2 mRNA in clinical specimens., PMID:27175478
Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses., PMID:26658766
For research use only. Not for human or drug use.
